New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
08:15 EDTCVMCEL-SCI receives regulatory clearance to expand Phase III trial into Austria
CEL-SCI Corporation announced that it has received regulatory clearance from the Austrian Federal Office for Safety in Health Care to begin patient enrollment in the companyís Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine. Austria is the 14th country to participate in CEL-SCIís trial which is already active in numerous clinics around the world. CEL-SCIís Phase III trial is assessing the use of the companyís Multikine immunotherapy as a first line treatment for patients diagnosed with advanced primary head and neck cancer, prior to standard of care, which involves surgery, chemotherapy, and/or radiation therapy. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors. Further expansion of CEL-SCIís Phase III head and neck cancer trial is underway with a goal to have a total of 880 patients enrolled through about 100 clinical centers through by the end of 2015. Over 200 patients are already enrolled in, and being treated with Multikine.
News For CVM From The Last 14 Days
Check below for free stories on CVM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
08:11 EDTCVMCEL-SCI cleared to begin patient enrollment
Subscribe for More Information
July 22, 2014
08:32 EDTCVMCEL-SCI receives clearance to expand Multikine Phase III trial to Turkey
Subscribe for More Information
July 17, 2014
08:45 EDTCVMCEL-SCI expands Phase III head and neck cancer trial into Sri Lanka
CEL-SCI announced that Sri Lankaís Ministry of Health has cleared the company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine in Sri Lanka. This follows similar clearance to conduct the Phase III study in the UK and Austria during the past weeks. Further expansion of the trial is underway with a goal to have a total of 880 patients enrolled through about 100 clinical centers in 20 countries by the end of 2015. The trial, which already has over 220 patients enrolled, is assessing the companyís investigational immunotherapeutic agent Multikine as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.
July 15, 2014
08:02 EDTCVMCEL-SCI receives $225K NIH research grant
CEL-SCI announced that it has been awarded a Phase I Small Business Innovation Research grant in the amount of $225K from the National Institute of Arthritis Muscoskeletal and Skin Diseases, which is part of the National Institutes of Health. The grant will fund the further development of CEL-SCIís LEAPS technology as a potential treatment for rheumatoid arthritis. The NIH grant was awarded based on preliminary data by Tibor Glantís team in collaboration with CEL-SCI showing that the administration of a proprietary peptide using CEL-SCI's LEAPS technology prevented the development, and lessened the severity, including inflammation, of experimental RA when it was administered after the disease was induced in the animals. This data was presented in May 2013 by Daniel Zimmerman, CEL-SCIís senior vice president of research, cellular immunology, at the symposium on ďTherapeutic Approaches to AutoimmunityĒ during the American Association of Immunologists 100th annual meeting in Honolulu, Hawaii.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use